Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Nexavar

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
........................................................................................................................................................ 2 1 Chapter One: Introduction .......................................................................................................................... 6 1.1 Research background .......................................................................................................................... 6 1.2 Research questions .............................................................................................................................. 8 1.3 Justifications for the research .............................................................................................................. 8 1.4 Methodology ....................................................................................................................................... 9 1.5 Structure of thesis .............................................................................................................................. 10 2 Chapter Two: Compulsory License Overview: Focus on “Failure to Work” .......................................... 11 2.1 The Operation of the Compulsory License Regime .......................................................................... 11 2.1.1 Recognized grounds ....................................................................................................................... 12 2.2.1 Scope and duration ......................................................................................................................... 14 2.1.4 Remuneration ................................................................................................................................. 19 2.2 Compulsory License among other patent limitations ........................................................................ 20 3 Chapter Three: The Interface between Human Rights and Patent Law: The Correlation between Access to Medicines and “Failure to Work” ........................................................................................................... 23 3.1 The convergence of Access to Medicines and “Failure to Work” .................................................... 23 3.1.1 Subjugation .................................................................................................................................... 23 3.1.2 Integration ...................................................................................................................................... 24 3.1.3 Coexistence .................................................................................................................................... 26 3.2 The Content of Access to Medicines ................................................................................................. 28 3.2.1 Availability and Affordability ........................................................................................................ 30 4 Chapter four: The analyze of the Bayer Nexavar case ............................................................................ 32 4.1 Bayer in India .................................................................................................................................... 32 4.2. Before the Controller of Patents in Mumbai .................................................................................... 32 4.3 Before the Before the Intellectual Property Appellate Board ........................................................... 36 4.4 On the Ability of “Failure to Work” to Promotion Access to Medicines ......................................... 41 5 Chapter five: Conclusion .......................................................................................................................... 44 5.1 Conclusion and recommendations .................................................................................................... 44 6 Chapter six: Bibliography ........................................................................................................................ 45 6.1 Reference Table ................................................................................................................................ 45 
Is this relevant?
2012
2012
Sorafenib (Nexavar®, BAY 43-9006) is a novel multikinase inhibitor that has been recently approved for the treatment of advanced… Expand
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2011
2011
Two separate clinical studies of advanced hepatocarcinoma patients recently reported that the multikinase inhibitor sorafenib… Expand
Is this relevant?
2010
2010
The majority of kinase inhibitors developed to date are competitive inhibitors that target the ATP binding site; however, recent… Expand
Is this relevant?
2010
2010
OBJECTIVE To study the therapeutic effects of Nexavar on liver cancer and its relation to the expressions of Ki-67 and CD34… Expand
Is this relevant?
2009
2009
Inhibition of receptor tyrosine kinases (RTKs) such as vascular endothelial growth factor receptors (VEGFRs) and platelet-derived… Expand
  • table 2
  • figure 1
  • table 1
  • table 3
  • table 5
Is this relevant?
2009
2009
Curative management of early-stage hepatocarcinoma may include partial hepatic resection, liver transplantation or tumoral… Expand
Is this relevant?
2008
2008
PURPOSE To report on the effect of oral nexavar (Sorafenib) treatment in one patient with neovascular age-related macular… Expand
Is this relevant?
2008
2008
Sorafenib (NexavarⓇ) is an oral multikinase inhibitor that was recently approved for use in metastatic renal cancer. It is… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Activating mutations in Ras and B-RAF were identified in several human cancers. In addition, several receptor tyrosine kinases… Expand
Is this relevant?